Lymphoma

LYMPHOMA ADVISOR

HEADLINES
TREATMENT REGIMENS
DRUG INFORMATION

FEATURED CONTENT

COVID-19 Vaccination and Imaging Misinterpretation: An Interview With Lacey McIntosh, DO, MPH

Oncologists and patients should be aware of the potential manifestations of the COVID-19 vaccination on imaging and the consequences this might have on disease assessment, treatment monitoring, and decision-making.
Patients Continue to Be Inadequately Informed of Risk for Breast Implant-Associated ALCL

Although the risk for breast implant-associated anaplastic large-cell lymphoma (BIA-ALCL) has been well-documented, patients considering breast implants continue to be inadequately informed of the propensity for disease development.
Bystander Killing Could Be Key Factor in CAR-T Success in Non-Hodgkin Lymphoma

Chimeric antigen receptor (CAR)-T cells can kill off-target tumor cells in the vicinity of the target cells, a phenomenon known as bystander killing. Modulating the expression of the protein mediating this process—Fas—could be a strategy to improve CAR-T efficacy.
Considerations for Secondary Primary Malignancy Development in Follicular Lymphoma

As follicular lymphoma (FL) survival rates have improved, concern that patients are at increased risk for the development of a secondary primary malignancy (SPM) has arisen.
Current Treatment Options for Nodular Lymphocyte-Predominant Hodgkin Lymphoma

Investigators summarize current literature surrounding the treatment of NLPHL and discuss treatment considerations for 2 clinical cases.

LYMPHOMA NEWS

Low Risk of Lymphoma, But Not Other Cancers, With Topical Calcineurin Inhibitors

May 7, 2021

Serious Long-Term Adverse Events Decreased in Pediatric Hodgkin Lymphoma

May 4, 2021

Most patients achieved deep remission after a 14-month regimen of obinutuzumab, ibrutinib, and venetoclax.

Change in Health Behaviors Affect Quality of Life in Lymphoma Survivors

April 30, 2021

Mogamulizumab Offers Glimmer of Hope for Relapsed T-cell Lymphomas

Camrelizumab Plus Decitabine Improve Outcomes in Relapsed/Refractory Hodgkin Lymphoma

April 30, 2021

Computer illustration of Burkitt lymphoma.

Prophylactic HD-MTX Does Not Improve CNS Relapse, Survival Outcomes in High-Risk DLBCL

April 28, 2021

Next post in Lymphoma

Serious Long-Term Adverse Events Decreased in Pediatric Hodgkin Lymphoma